New eye imaging could reveal hidden clues to vision loss

NCT ID NCT07747662

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study explores whether combining three eye-imaging techniques can reveal how structural damage in the retina relates to vision loss in people with geographic atrophy, a form of age-related macular degeneration. Researchers will use OCT scans, ultra-high-resolution AOSLO imaging, and microperimetry to measure retinal sensitivity. The goal is to validate OCT-based measurements of photoreceptor damage by comparing them with direct visualization and functional tests. Ten participants from a larger study will undergo these imaging procedures to see if structural changes correlate with vision function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO), Microperimetry, and Optical Coherence Tomography (OCT) imaging devices
What this could lead to
If successful, this could validate OCT as a reliable biomarker for vision loss in geographic atrophy, improving how the disease is monitored and treated.
What could go wrong
This is a small, early-stage validation study with only 10 participants, so results may not generalize. Imaging procedures are time-consuming and require specialized equipment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Wisconsin

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.